| Indicators | Browse All

Clene Inc. (CLNN)

Consumer Defensive | Packaged Foods | Salt Lake City, United States | NasdaqCM
6.19 USD -0.20 (-3.130%) ⇩ (July 14, 2026, 4 p.m. EDT)

Short-term:★☆☆☆☆Long-term:⯪☆☆☆☆Dividends:☆☆☆☆☆
Hot Take | July 11, 2026, 6:18 a.m. EDT

The immediate outlook is severely clouded by a catastrophic multi-year price collapse and deteriorating fundamentals. While recent headlines celebrate FDA updates and a 20% surge, the underlying business is bleeding value: revenue has contracted by over 80%, operating margins are deeply negative, and free cash flow is massively outflowing. The price action confirms this distress, having lost 98% of its value over the last six years with four consecutive years of decline. This is not a value opportunity; it is a failing enterprise where the market has correctly priced out the risk of continued erosion. With no dividend to provide income and a balance sheet showing negative book value, there is no margin of safety here. The recent rally appears to be a speculative reaction to regulatory news rather than a reversal of the company's structural decline.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.061643
AutoARIMA0.066151
MSTL_1150.076213
MSTL0.087542
AutoETS0.089903
MSTL_900.126566
MSTL_90_1150.204723

Forecast horizon: 60 days | Selected: AutoTheta

Forecast Reliability
Score 35%
H-stat 0.27
Ljung-Box p 0.000
Jarque-Bera p 0.295
Excess Kurtosis 0.16
Attribute Value
Sector Consumer Defensive
Revenue per Share 0.013
Market Cap 79,097,720
Forward P/E -3.46
Beta 0.92
Previous Name Clene Nanomedicine Inc.
Website https://clene.com

Info Dump

Attribute Value
52 Week Change 0.72702706
Address1 6,550 South Millrock Drive
Address2 Suite G50
All Time High 356.4
All Time Low 2.28
Ask 7.94
Ask Size 2
Average Daily Volume10 Day 55,960
Average Daily Volume3 Month 502,757
Average Volume 502,757
Average Volume10Days 55,960
Beta 0.923
Bid 4.57
Bid Size 2
Book Value -1.597
City Salt Lake City
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 6.19
Current Ratio 1.935
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 6.55
Day Low 6.17
Display Name Clene
Earnings Timestamp End 1,755,088,200
Earnings Timestamp Start 1,755,088,200
Ebitda -19,622,000
Ebitda Margins 0.0
Enterprise To Ebitda -4.852
Enterprise To Revenue 710.498
Enterprise Value 95,206,720
Eps Current Year -1.405
Eps Forward -1.79
Eps Trailing Twelve Months -3.25
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 6.2806
Fifty Day Average Change -0.090600014
Fifty Day Average Change Percent -0.0144253755
Fifty Two Week Change Percent 72.702705
Fifty Two Week High 13.5
Fifty Two Week High Change -7.31
Fifty Two Week High Change Percent -0.5414815
Fifty Two Week Low 3.25
Fifty Two Week Low Change 2.94
Fifty Two Week Low Change Percent 0.9046154
Fifty Two Week Range 3.25 - 13.5
Financial Currency USD
First Trade Date Milliseconds 1,539,869,400,000
Float Shares 10,501,979
Forward Eps -1.79
Forward P E -3.4581006
Free Cashflow -11,576,125
Full Exchange Name NasdaqCM
Full Time Employees 76
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.82835996
Gross Profits 111,000
Has Pre Post Market Data 1
Held Percent Insiders 0.17063
Held Percent Institutions 0.20438999
Implied Shares Outstanding 12,778,307
Industry Packaged Foods
Industry Disp Packaged Foods
Industry Key packaged-foods
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,720,656,000
Last Split Factor 1:20
Long Business Summary Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Long Name Clene Inc.
Market us_market
Market Cap 79,097,720
Market State PRE
Max Age 86,400
Message Board Id finmb_339429732
Most Recent Quarter 1,774,915,200
Name Change Date 2,026-07-15
Net Income To Common -33,513,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 81,653,381
Number Of Analyst Opinions 5
Open 6.24
Operating Cashflow -18,063,000
Operating Margins -137.4
Payout Ratio 0.0
Phone 801 676 9695
Prev Name Clene Nanomedicine Inc.
Previous Close 6.39
Price Eps Current Year -4.405694
Price Hint 2
Price To Book -3.8760176
Price To Sales Trailing12 Months 590.2815
Profit Margins 0.0
Quick Ratio 1.404
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.19999981
Regular Market Change Percent -3.1298876
Regular Market Day High 6.55
Regular Market Day Low 6.17
Regular Market Day Range 6.17 - 6.55
Regular Market Open 6.24
Regular Market Previous Close 6.39
Regular Market Price 6.19
Regular Market Time 1,784,059,201
Regular Market Volume 73,125
Return On Assets -0.56057
Revenue Growth -0.815
Revenue Per Share 0.013
Sand P52 Week Change 0.20365608
Sector Consumer Defensive
Sector Disp Consumer Defensive
Sector Key consumer-defensive
Shares Outstanding 12,778,307
Shares Percent Shares Out 0.0774
Shares Short 988,908
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 1,125,471
Short Name Clene Inc.
Short Percent Of Float 0.1035
Short Ratio 9.57
Source Interval 15
State UT
Symbol CLNN
Target High Price 50.0
Target Low Price 20.0
Target Mean Price 32.2
Target Median Price 30.0
Total Cash 5,939,000
Total Cash Per Share 0.465
Total Debt 22,048,000
Total Revenue 134,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -3.25
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 6.548
Two Hundred Day Average Change -0.3579998
Two Hundred Day Average Change Percent -0.054673154
Type Disp Equity
Volume 73,125
Website https://clene.com
Zip 84,121